We are live on ! Find out more
CC

Caxton Corporation Portfolio holdings

AUM $4.02M
1-Year Est. Return 256.08%
This Fund
S&P 500
This Quarter Est. Return
+40.6%
1 Year Est. Return
+256.08%
3 Year Est. Return
+777.99%
5 Year Est. Return
+744.68%
10 Year Est. Return
+18,621.85%
AUM
$9.85M
AUM Growth
+$4.77M
Cap. Flow
+$2.44M
Cap. Flow %
24.76%
Top 10 Hldgs %
99.88%
Holding
13
New
1
Increased
3
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
GLD icon
SPDR Gold Trust
GLD
+$1.11M
2
RZLT icon
Rezolute
RZLT
+$1.06M
3
ELVN icon
Enliven Therapeutics
ELVN
+$248K
4
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$83.8K

Top Sells

Rank Stock Value
1
CRDF icon
Cardiff Oncology
CRDF
+$41.7K
2
ACET icon
Adicet Bio
ACET
+$13.2K
3
LXEO icon
Lexeo Therapeutics
LXEO
+$1.71K

Sector Composition

Rank Sector Weight
1 Healthcare 81.56%
2 Financials 3.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RZLT icon
1
Rezolute
RZLT
$421M
$7.15M 72.6%
1,603,986
+285,019
+22% +$1.06M
GLD icon
2
SPDR Gold Trust
GLD
$130B
$1.51M 15.32%
4,952
+3,654
+282% +$1.11M
BRK.B icon
3
Berkshire Hathaway Class B
BRK.B
$1.06T
$307K 3.12%
632
+165
+35% +$83.8K
ELVN icon
4
Enliven Therapeutics
ELVN
$3.63B
$263K 2.67%
+13,097
New +$248K
DFTX
5
Definium Therapeutics
DFTX
$5.85B
$221K 2.24%
34,073
– –
CMPX icon
6
Compass Therapeutics
CMPX
$378M
$113K 1.15%
43,465
– –
BCAX
7
Bicara Therapeutics
BCAX
$1.81B
$102K 1.03%
10,941
– –
KYTX icon
8
Kyverna Therapeutics
KYTX
$452M
$70.6K 0.72%
22,981
– –
LXEO icon
9
Lexeo Therapeutics
LXEO
$358M
$69.7K 0.71%
17,332
-519
-3% -$1.71K
IKT icon
10
Inhibikase Therapeutics
IKT
$316M
$32K 0.32%
16,393
– –
CNTX icon
11
Context Therapeutics
CNTX
$56.5M
$12.1K 0.12%
18,403
– –
ACET icon
12
Adicet Bio
ACET
$76.8M
– –
-1,093
Closed -$13.2K
CRDF icon
13
Cardiff Oncology
CRDF
$59.8M
– –
-13,287
Closed -$41.7K

Similar funds

PCM
Pathway Capital Management Irvine, California $4.3M AUM 62.8% 1-Year Est. Return
EAMS
Eurizon Asset Management Slovakia Bratislava $3.4M AUM
RCP
RPM Capital Partners New York $3.34M AUM 43.17% 1-Year Est. Return
RA
Ritter Alpha New York $4.78M AUM
CGA
Compound Global Advisors Mercer Island, Washington $3.22M AUM 30.08% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ABA
American Beacon Advisors Irving, Texas $5.08M AUM 20.11% 1-Year Est. Return
UOMF
University of Maryland Foundation Adelphi, Maryland $5.1M AUM 10.69% 1-Year Est. Return

Caxton Corporation's Q2 2025 Portfolio in Review

As of Q2 2025, Caxton Corporation held 13 positions worth $9.85M, up 94% from $5.08M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Caxton Corporation deployed $2.44M of net new capital in Q2 2025, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Enliven Therapeutics: 13,097 shares worth $263K.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 88% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Lexeo Therapeutics, an estimated $1.71K trimmed.

  • Caxton Corporation's largest Q2 2025 buy was Enliven Therapeutics: 13,097 shares worth $263K.
  • Caxton Corporation added most to SPDR Gold Trust in Q2 2025, an estimated $1.11M increase.
  • Caxton Corporation's biggest Q2 2025 reduction was Lexeo Therapeutics, cutting an estimated $1.71K.
  • Caxton Corporation fully exited Cardiff Oncology in Q2 2025, selling an estimated $41.7K.
  • Caxton Corporation's ten largest holdings make up 100% of its $9.85M portfolio in Q2 2025.
  • Caxton Corporation opened 1 new position and closed 2 in Q2 2025.
  • Caxton Corporation's portfolio value rose 94% quarter-over-quarter to $9.85M.

Based on Caxton Corporation's 13F filing for Q2 2025, filed 14 Aug 2025.